South Korea-based clinical-stage biopharmaceutical company TiumBio Co., Ltd. (Kosdaq: 321550) announced on Friday that it has dosed its first patient in its phase two clinical trial of its oral immuno-oncology drug TU2218.
TU2218 is a potentially first-in-class dual inhibitor targeting transforming growth factor beta receptor 1 (TGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2). It is expected to improve the efficacy of immune checkpoint inhibitors (ICIs) by blocking TGF-beta and VEGF pathways.
During Phase 1a and 1b clinical trials, the company assessed the safety, pharmacokinetics and pharmacodynamics of TU2218 as a monotherapy and in combination with Keytruda (pembrolizumab) in 41 patients with advanced solid tumours. These profiles were used to assess the dose levels for Phase two trials. The Phase 2a trial is engineered to evaluate the safety and efficacy of TU2218 in combination with Keytruda in patients with head and neck squamous cell carcinoma (HNSCC), biliary tract cancer (BTC), and colorectal cancer (CRC).
The Phase 2 trial begins at Seoul National University Hospital and Asan Medical Center in South Korea, which is planned to expand to hospitals in the United States. The first dose was administered to an HNSCC patient.
The company says that in the Phase 1b trial, among 10 patients with advanced solid tumours that received a 195mg daily dose (the determined dose for Phase 2) of TU2218 with Keytruda, three patients achieved partial response (PR) and five patients had stable disease (SD), yielding an 80% disease control rate (DCR).
Galderma's nemolizumab recommended for NHS funding in England and Wales for atopic dermatitis
Merck launches Phase 3 trial for dengue vaccine candidate V181
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
Mezzion Pharma obtains USD20m funding for udenafil Phase 3 clinical development for Fontan patients
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
MaxCyte and Ori Biotech partner to advance autologous cell therapy manufacturing
OptiBiotix announces publication of positive SlimBiome study in European Journal of Nutrition
Crossject advances paediatric development of ZEPIZURE Junior for epilepsy crisis management
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies